Pfizer (NYSE:PFE) Trading Up 0.8%

Pfizer Inc. (NYSE:PFE) shares were up 0.8% during mid-day trading on Monday . The company traded as high as $28.26 and last traded at $28.02. Approximately 11,031,535 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 42,765,719 shares. The stock had previously closed at $27.81.

Analyst Ratings Changes

PFE has been the topic of a number of analyst reports. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Morgan Stanley upped their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Pfizer has a consensus rating of “Hold” and an average price target of $36.00.

Pfizer Trading Up 1.8 %

The stock has a market cap of $160.11 billion, a price-to-earnings ratio of -471.17, a P/E/G ratio of 1.17 and a beta of 0.63. The business’s 50 day moving average is $26.92 and its 200 day moving average is $28.12. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.23 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.94%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

Institutional Investors Weigh In On Pfizer

Several large investors have recently modified their holdings of PFE. Edmond DE Rothschild Holding S.A. lifted its position in Pfizer by 3.0% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 2,689,616 shares of the biopharmaceutical company’s stock worth $74,637,000 after acquiring an additional 77,752 shares during the period. Cozad Asset Management Inc. raised its position in Pfizer by 12.9% during the 1st quarter. Cozad Asset Management Inc. now owns 43,837 shares of the biopharmaceutical company’s stock worth $1,216,000 after buying an additional 5,005 shares during the last quarter. Richard C. Young & CO. LTD. lifted its stake in shares of Pfizer by 115.9% in the 1st quarter. Richard C. Young & CO. LTD. now owns 417,506 shares of the biopharmaceutical company’s stock worth $11,586,000 after acquiring an additional 224,125 shares during the period. MAI Capital Management boosted its holdings in shares of Pfizer by 11.8% in the first quarter. MAI Capital Management now owns 711,890 shares of the biopharmaceutical company’s stock valued at $19,755,000 after acquiring an additional 74,983 shares in the last quarter. Finally, QCM Cayman Ltd. purchased a new position in Pfizer during the first quarter worth about $264,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.